Physician profile
Robin Riley
NPI 1215390406
$5,017.49
in general payments reported to CMS, 2019-2025
15 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2022: $792 · 2023: $3,747 · 2024: $87.22 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,113 · Food and Beverage: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,112.69 |
| Food and Beverage | $483.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,669.48 | 2023-2024 | Davinci Xi, Da Vinci Surgical System |
| Zimmer Biomet Holdings, INC. | $395.08 | 2022 | |
| Davol INC. | $337.27 | 2022 | |
| Kerecis Limited | $245.72 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Covidien LP | $128.80 | 2019 | |
| Abbvie INC. | $52.18 | 2024 | |
| Janssen Biotech, INC. | $49.94 | 2022-2023 | Erleada, Darzalex, Imbruvica |
| Merck Sharp & Dohme LLC | $24.22 | 2024 | Keytruda, Welireg |
| Beigene USA, INC. | $20.73 | 2023 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $17.03 | 2022 | |
| Caris Mpi, INC. | $16.70 | 2025 | Mi Cancer Seek |
| Eisai INC. | $16.37 | 2022 | |
| Daiichi Sankyo INC. | $15.91 | 2023 | Enhertu |
| Mirati Therapeutics, INC. | $14.11 | 2023 | Krazati |
| Lilly USA, LLC | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.